加倍剂量阿托伐他汀对糖尿病肾病患者血脂及超敏C反应蛋白的影响

目的研究加倍剂量阿托伐他汀对糖尿病肾病患者血脂及超敏C反应蛋白的影响。方法将160例糖尿病肾病患者随机分为给予加倍剂量阿托伐他汀(40 mg、口服、2次/d)治疗的观察组和常规剂量阿托伐他汀(20 mg、口服、2次/d)治疗的对照组各80例,检测患者血脂及超敏C反应蛋白(CRP)水平。结果观察组甘油三酯(2.86±0.31)mmol/L、胆固醇(1.13±0.16)mmol/L、低密度脂蛋白(2.12±0.29)mmol/L、载脂蛋白B(1.01±0.16)g/L、C反应蛋白水平(5.61±0.67)ng/L及异常例数(5例)明显低于对照组,高密度脂蛋白(1.32±0.17)mmol/L和载脂蛋白A-Ⅰ(1.78±0.20)g/L水平明显高于对照组(均P<0.05);CRP水平与甘油三酯、胆固醇、低密度脂蛋白和载脂蛋白B水平呈正相关(95%CI:1.385~1.723、1.228~1.652、0.891~1.289、1.184~1.582),与高密度脂蛋白和载脂蛋白A-Ⅰ水平呈负相关(95%CI:-1.384^-1.013、-0.930^-0.536)。结论倍剂量阿托伐他汀降脂治疗能够有效改善血脂代谢情况和C反应蛋白水平。

Objective To study the effects of double dose of atorvastatin on blood lipid and high sensitive CRP in patients with diabetic nephropathy. Methods Patients with diabetic nephropathy were collected and divided into observation group（given double dose atorvastatin,40 mg） and control group（given conventional doses,20 mg）. The CLIP, blood lipids level were observed. Results TC（2.86±0.31 ）mmol/L, TG（1.13±0.16） mmol/L, LDL（2.12±0.29）mmol/L, ApoB（1.01±0.16）g/L, CRP content（5.61±0.67）ng/L and CRP abnormalities cases （5 cases） of observation group were significantly lower than control group（all P〈 0.05 ）, .HDL（1.3210.17）mmol/L, apoA- I （1.78±0.20）g/L were significantly higher than control group; CRP level was positively correlated to TC, TG, LDL, ApoB, CRP content（95%Cl： 1.385-1.723, 1.228-1.652,0.891-1.289, 1.184-1.582） and negatively correlated to HDL, apoA- I content（95%CI： - 1.384-- 1.013. -0.930-- 0.536）. Conclusion Double dose atorvastatin can effectively improve lipid metabolism and C reactive protein levels.